Cite
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
MLA
Fang, Wenfeng, et al. “Camrelizumab (SHR-1210) Alone or in Combination with Gemcitabine plus Cisplatin for Nasopharyngeal Carcinoma: Results from Two Single-Arm, Phase 1 Trials.” Lancet Oncology, vol. 19, no. 10, Oct. 2018, pp. 1338–50. EBSCOhost, https://doi.org/10.1016/S1470-2045(18)30495-9.
APA
Fang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., Zhang, Y., Chen, L., Zhou, N., Zhao, Y., Hou, X., Yang, Q., & Zhang, L. (2018). Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncology, 19(10), 1338–1350. https://doi.org/10.1016/S1470-2045(18)30495-9
Chicago
Fang, Wenfeng, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, et al. 2018. “Camrelizumab (SHR-1210) Alone or in Combination with Gemcitabine plus Cisplatin for Nasopharyngeal Carcinoma: Results from Two Single-Arm, Phase 1 Trials.” Lancet Oncology 19 (10): 1338–50. doi:10.1016/S1470-2045(18)30495-9.